EP1105538A2 - COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES - Google Patents
COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEESInfo
- Publication number
- EP1105538A2 EP1105538A2 EP99945051A EP99945051A EP1105538A2 EP 1105538 A2 EP1105538 A2 EP 1105538A2 EP 99945051 A EP99945051 A EP 99945051A EP 99945051 A EP99945051 A EP 99945051A EP 1105538 A2 EP1105538 A2 EP 1105538A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- stearoyl
- coa desaturase
- human
- skm
- scd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 63
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 title description 9
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims abstract description 154
- 108010087894 Fatty acid desaturases Proteins 0.000 claims abstract description 70
- 102000055981 human SCD1 Human genes 0.000 claims abstract description 70
- 230000014509 gene expression Effects 0.000 claims abstract description 64
- 230000000694 effects Effects 0.000 claims abstract description 55
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 46
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 46
- 210000004927 skin cell Anatomy 0.000 claims abstract description 25
- 208000017520 skin disease Diseases 0.000 claims abstract description 24
- 230000007423 decrease Effects 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 230000002159 abnormal effect Effects 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims abstract description 13
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 9
- 238000001415 gene therapy Methods 0.000 claims abstract description 8
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims abstract 18
- 239000002299 complementary DNA Substances 0.000 claims description 84
- 210000003491 skin Anatomy 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 40
- 108020004999 messenger RNA Proteins 0.000 claims description 28
- 239000013604 expression vector Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000011200 topical administration Methods 0.000 claims description 11
- 201000004384 Alopecia Diseases 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- 206010000496 acne Diseases 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010020864 Hypertrichosis Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 241000518994 Conta Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 27
- 241000699660 Mus musculus Species 0.000 abstract description 2
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 127
- 241000699666 Mus <mouse, genus> Species 0.000 description 49
- 239000000523 sample Substances 0.000 description 43
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 27
- 108700026244 Open Reading Frames Proteins 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 25
- 210000004185 liver Anatomy 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 22
- 210000001732 sebaceous gland Anatomy 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 description 20
- 210000004209 hair Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 101100309601 Mus musculus Scd3 gene Proteins 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 210000003780 hair follicle Anatomy 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 238000007901 in situ hybridization Methods 0.000 description 14
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 13
- 150000004665 fatty acids Chemical class 0.000 description 13
- 239000011159 matrix material Substances 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 210000002510 keratinocyte Anatomy 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 108020005345 3' Untranslated Regions Proteins 0.000 description 9
- 101100309604 Homo sapiens SCD5 gene Proteins 0.000 description 9
- 101100101423 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBI4 gene Proteins 0.000 description 9
- 101150042597 Scd2 gene Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 108020003589 5' Untranslated Regions Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000699800 Cricetinae Species 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000000106 sweat gland Anatomy 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000009114 Fatty acid desaturases Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023045 Untranslated Region Proteins 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000037429 base substitution Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- -1 fatty acid lipid Chemical class 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 4
- 230000001096 hypoplastic effect Effects 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 101150097713 SCD1 gene Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000004919 hair shaft Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940049964 oleate Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 102000007605 Cytochromes b5 Human genes 0.000 description 2
- 108010007167 Cytochromes b5 Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 101100202503 Mus musculus Scd2 gene Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 101150048395 SCD gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000023549 cell-cell signaling Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical group 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 2
- QBYOCCWNZAOZTL-MDMKAECGSA-N palmitoleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QBYOCCWNZAOZTL-MDMKAECGSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000016899 Cytochrome-B(5) Reductase Human genes 0.000 description 1
- 108010028689 Cytochrome-B(5) Reductase Proteins 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100034577 Desmoglein-3 Human genes 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 206010016260 Fatty acid deficiency Diseases 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 101100215143 Mus musculus Scd1 gene Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Natural products NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000077 angora Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001208 inner root sheath cell Anatomy 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid group Chemical group C(CCCCCCC\C=C/CCCCCC)(=O)O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- This invention relates to the diagnosis and treatment of skin disorders characterized by abnormal stearoyl-CoA desaturase expression and activity.
- the invention also relates to various means of identifying agents useful for treating such disorders.
- Fatty acid desaturases are enzymes that catalyze the insertion of a double bond in fatty acids.
- This enzyme introduces a cis-double bond at the delta- 9 position of fatty acyl-CoA's to produce palmitoleoyl and oleoyl-CoA.
- Mammalian fatty acid desaturases are structurally similar to each other. They are integral membrane, iron-containing enzymes that catalyze the NADH- and 0 2 - dependent formation of double bonds into methylene- interrupted fatty acyl chains .
- Various forms of mammalian stearoyl-CoA desaturase (“SCD”) have been isolated from rat, mouse, human, bovine (St. John, et al . 1991), ovine, porcine, and hamster.
- SCD mammalian stearoyl-CoA desaturase
- the coding regions of mouse, human and rat SCD sequences show over 80% nucleotide sequence identity. They apparently share a similar exonic structure, but differ markedly in upstream regulatory regions (Mihara 1990) .
- Stearoyl-CoA desaturase is responsible for the production of unsaturated fatty acids, which are required for energy and lipid metabolism, membrane structure, and signal transduction.
- the expression of stearoyl-CoA desaturase in the skin suggests an important role for unsaturated fatty acids in skin homeostasis, and specifically in the function of the pilosebaceous unit and the eccrine sweat gland.
- SCD is the enzyme responsible for the committed step in unsaturated fatty acid ("UFA") synthesis, and as such is the key point of metabolic control in this pathway.
- UFA'S are important for three major reasons. UFA'S are key components of cellular membranes. Triglycerides contain UFA'S and are a major component of energy metabolism. Finally, UFA'S play an important role in stimulating lipid- activated kinases during signal transduction.
- SCD1 SCD1
- M-SCD2 SCD2
- a critical step in the biosynthesis of unsaturated fatty acids is the introduction of the first cis-double bond in the ⁇ 9 position (between carbons 9 and 10) (Ntambi 1995) .
- the iron-containing stearoyl-CoA desaturase enzyme catalyzes this oxidative step. In this reaction, electrons flow from NADPH through NADH- cytochrome b5 reductase to cytochrome b5. Cytochrome b5 is the direct electron donor to the desaturase.
- Stearoyl-CoA desaturase is believed to utilize iron in an oxidative-reduction reaction transferring electrons to molecular oxygen with the production of H 2 0 (Strittmatter, et al . 1974).
- the rate-limiting step in this reaction is at the desaturase. It is this factor which is cyanide-sensitive and limits the overall desaturation rate (Oshino 1972; Oshino, et al . 1972).
- Acyl CoA derivatives of fatty acids containing 12 to 19 carbon residues are required for desaturase activity. (Enoch, et al . 1976). Shorter chain acyl CoA derivatives, free CoA and free fatty acids do not appear to bind to the enzyme (Enoch, et al . 1976) . Additionally, SCD activity is affected by metal ions (Wahle, 1975) .
- Palmitate and stearate are converted into palmitoleoyl -CoA and oleoyl-CoA, respectively, by the enzyme.
- Palmitoleic and oleic acids are the major unsaturated fatty acid constituents of phospholipids and triacylglycerols . The former is central to membrane structure and the latter to the lipid store found in adipocytes. The ratio of stearic to oleic acid is one of the factors influencing cell membrane fluidity.
- M-SCDl Two mouse SCD genes have been identified, and designated M-SCDl and M-SCD2.
- M-SCDl cDNA was isolated from 3T3-L1 preadipocytes which had been shown to express M-SCDl upon differentiation (preadipocytes into adipocytes) (Ntambi, et al . 1988).
- the M-SCDl gene encodes a 4.9kb mRNA.
- the predicted amino acid sequence of the mouse 3T3 adipocyte SCD exhibits 92% similarity to rat liver SCDl.
- the SCDl gene spans 15 kb and contains 6 exons and 5 introns .
- the 5' end of the SCD-1 gene shows a canonical TATA box (Ntambi, et al . 1988).
- a region similar to the binding site for the nuclear transcription factor, Spl, is present.
- Upstream of the transcription initiation site are regions homologous to the fat- specific transcription element FSE2.
- Core consensus sequences for cAMP and glucocorticoid regulatory elements are present (Ntambi, et al . 1988) .
- the PPAR receptor localizes to an
- C/EBP can bind to the M- SCD1 promoter and activate transcription during the late stage of adipocyte differentiation (Christy, et al. 1989) .
- the M-SCD2 gene spans approximately 15 kb and, like M-SCDl and rat SCD, consists of 6 exons and 5 introns (Kaestner, et al . 1989; Mihara 1990).
- the promoter regions for M-SCD2 have also been characterized (Kaestner, et al . 1989).
- the 5' end of M-SCD2 lacks a typical 5' TATA box, but has two CCAAT boxes.
- the M-SCD2 promoter contains a region (located between nucleotides -54 to -201) which shows a 77% sequence identity to a region in the M-SCDl promoter. It contains a site similar to the nuclear transcription factor, Spl, and an element with homology to the core consensus sequence of the glucocorticoid regulatory element (Kaestner, et al . 1989).
- the SCD genes have tissue-specific expression patterns. Under normal dietary states, M-SCDl mRNA' s are expressed constitutively in adipose, but not hepatic, tissue. Their expression is induced in liver in response to a fat-free, high-carbohydrate diet. M- SCD2 mRNA's are constitutively expressed in brain and induced in kidney, lung, spleen and adipose tissue in response to a high carbohydrate diet, but not expressed in liver under either condition (Kaestner, et al .
- the asejia mutation was first described in mice by Gates, et al . (1965) .
- the mutation arose as an autosomal recessive trait in the BA B/c mouse strain.
- Prominent elements of the phenotype include early loss of hair, scaly skin, and sebaceous glands that fail to fully develop. Since the meibomian glands are also hypoplastic, these mice also have eye problems.
- the ocular findings have been described as eye inflammation, photophobia and, finally, scarring of the eyelid with resultant blindness. Histologically (Josefowicz, et al .
- a human stearoyl-CoA desaturase cDNA of 712 bp was identified by PCR from adipose tissue (Li, et al . 1994) .
- This form is referred to herein as human adipose SCD ("HA-SCD").
- H-SCD human adipose SCD
- From the determined sequence it was seen that at the nucleotide level, the homology to the various mouse and rat SCD's is between 80-84%. The similarity in deduced peptide sequence between human and mouse SCD's is approximately 93%.
- RNAse protection demonstrates either no, little, or variable expression in normal esophagus, colon, and liver, respectively. Increased expression is seen in tumors derived from these three tissues.
- a human cDNA from liver is present in the database (Wisconsin Package Version 9.1, Genetics Computer Group, GCG, Madison, Wise. : accession number: Y13647) that contains part of the 5' and 3' UTR's and the complete ORF of SCD.
- This form is referred to herein as human liver SCD ("HL-SCD") .
- HL-SCD human liver SCD
- the identity of HL-SCD to HA-SCD is 98.6% (over the known sequence of HA-SCD); to M-SCDl is 76.2%; and to mouse SCD2 is 75.1%.
- identity of HL-SCD to HA-SCD is 98.7%, and is 83.9% to the M-SCDl.
- UFA'S are important for biological systems in the following ways: (1) as intermediates in lipid and energy metabolism (Neely, et al . 1974); (2) as components of triglycerides , which are a major form of cellular energy storage and the major component of circulating lipoprotein particles (Rosseneu, et al .
- Membrane fluidity has also been related to cell- cell signalling and cancer formation.
- the degree of membrane fluidity can affect the function of receptors (Clandimn, et al . 1991), and increased concentrations of membrane UFA'S have been detected in tumor cells, suggesting a role in neoplasia (Li, et al . 1994) .
- Many tumors show altered fatty acid profiles, especially an increase m oleate (Hrelia, et al . 1994).
- This change in membrane fluidity may confer changes in response to cell-cell and/or intra-cellular signalling. Indeed, the expression of high levels of yeast SCD in mammalian tumor cells increases membrane fluidity and greatly increases tumor necrosis factor signaling (Gyorfy, et al. 1997) .
- UFA'S are implicated in the regulation of cellular growth and differentiation.
- UFA's can co-activate various isoforms of protein kinase C (PKC) (Shinomura, et al . 1991). They can also alter the subcellular localization of PKC (Diaz-Guerra, et al . 1991), a process known to activate this enzyme.
- PKC plays an important role in the normal growth and differentiation of epidermal cells (Dlugosz, et al .
- UFA's are now recognized as activators of gene expression via transcription factors that bind to UFA's, such as peroxisome proliferator-activated receptor (Bocos, et al . 1995) and fatty acid-activated receptor (Ailhaud, et al . 1995).
- Phosphatidylinositol (Ptdlns) -3 , 4 , 5-triphosphate (P3) is a lipid second messenger that is formed by the phosphorylation of the 3 position of the inositol ring of PtdIns-4,5- bisphosphate (located in plasma membranes) by the receptor-activated phosphatidylinositol-3 -OH kinase [PI(3)K].
- PtdIns-3 , 4 , 5-P3 activates downstream kinases PDK1 , PDK2 , and PKB by recruiting these enzymes to the plasma membrane (Alessi, et al . 1998) . It has been shown that the most effective form of PtdIns-3 , 4 , 5-P3 for activating PKB is that with oleate at the 2 position of the phospholipid.
- the biological processes regulated by PI3 kinase and PKB pathways are pleiotropic, and include membrane trafficking, adhesion, cell growth, and survival (Toker, et al . 1997). Recently, Cadena, et al .
- MLD membrane fatty acid lipid desaturase
- the skin is recognized as a lipid-rich organ, the proper function of which depends on the integrity of lipid metabolism. It has long been known that essential fatty acid deficiency has profound effects on the skin. Prominent effects include scaling of skin and increased trans-epidermal water loss (Holman 1993). It is notable that the asebia mouse also manifests these changes .
- Atopic dermatitis a chronic inflammatory skin disease, is ameliorated by the administration of ⁇ - linolenic acid, indicating involvement of fatty acid metabolism in its pathogenesis (Youn, et al . 1998) .
- the integrity of the stratum corneum is heavily dependent on the lipid composition of the corneocytes, which act to promote hydrophobicity as well as maintain adhesion (Chen, et al . 1996).
- the maintenance of adhesion between the cuticle and the cortex of the hair shaft is dependent on specialized fatty acids, whose defects are manifest in hair from patients with Maple Syrup Urine Disease (Jones, et al . 1996) .
- the pilosebaceous unit is sensitive to alterations in fatty acid composition. This is futher demonstrated by data indicating that local deficiency of linolenic acid in the sebaceous gland leads to proliferation of the keratinocytes lining its duct. This in turn leads to the formation of comedones, the precursor to acne vulgaris (Downing, et al. 1986) .
- Hair matrix keratinocytes are the highly proliferative cells that give rise to the shaft and sheath of the hair. They are termed transient amplifying stem cells to indicate that their proliferation correlates with the growth phase of the hair, and that their quiescence correlates with the resting phase (i.e., no growth) of the hair follicle (Cotsarelis, et al . 1990).
- Hypertrichosis (Olsen, 1994) and hirsutism (Hughes, Jr. 1994) are diseases of the hair follicle that result from excessive growth. Alopecia encompasses several distinct diseases that result in a lack of hair growth (Rietscel 1996) .
- This invention provides a nucleic acid molecule encoding the human stearoyl-CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof .
- This invention also provides a nucleic acid molecule which, under suitable conditions, specifically hybridizes to a nucleic acid molecule encoding the human stearoyl-CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof.
- This invention further provides a method of diagnosing a human subject for a skin disorder characterized by an abnormal level of stearoyl-CoA desaturase expression, which comprises (i) obtaining a sample of skin mRNA from the subject; (ii) contacting the sample so obtained with an excess of the instant labeled nucleic acid molecule under conditions permitting hybridization of the labeled nucleic acid molecule with stearoyl-CoA desaturase mRNA present in the sample; (iii) removing un-hybridized labeled nucleic acid molecule from the sample; (iv) quantitatively determining the amount of hybridized labeled nucleic acid molecule present in the sample; and (v) comparing the amount determined in step (iv) with the amount determined using a skin mRNA sample from a normal human subject, a difference in these amounts being correlative of an abnormal level of stearoyl-CoA desaturase expression in the skin of the subject being diagnosed.
- This invention further provides an
- This invention still further provides a eukaryotic cell line which expresses human stearoyl-CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, wherein the cell is transfected with an expression vector encoding the desaturase.
- This invention provides a method for determining whether an agent increases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same, which comprises the steps of (i) contacting the agent under suitable conditions with a eukaryotic cell line expressing human stearoyl-CoA desaturase at a known level; and (ii) determining whether the stearoyl-CoA desaturase expression level increases after cellular contact with the agent, thereby determining whether the agent increases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same.
- This invention also provides a method for determining whether an agent decreases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same, which comprises the steps of (i) contacting the agent under suitable conditions with a eukaryotic cell line expressing human stearoyl-CoA desaturase at a known level; and (ii) determining whether the stearoyl-CoA desaturase expression level decreases after cellular contact with the agent, thereby determining whether the agent decreases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same.
- This invention further provides a method for determining whether an agent decreases the activity of human stearoyl-CoA desaturase in skin cells, which comprises the steps of (i) contacting the agent under suitable conditions with human stearoyl-CoA desaturase having a known level of activity; and (ii) determining whether the desaturase activity decreases after contact with the agent , thereby determining whether the agent decreases human stearoyl-CoA desaturase activity in skin cells.
- This invention further provides a method for determining whether an agent increases the activity of human stearoyl-CoA desaturase in skin cells, which comprises the steps of (i) contacting the agent under suitable conditions with human stearoyl-CoA desaturase having a known level of activity; and (ii) determining whether the desaturase activity increases after contact with the agent, thereby determining whether the agent increases human stearoyl-CoA desaturase activity in skin cells.
- This invention provides an antibody which specifically binds to human stearoyl-CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, and thereby inhibits the activity thereof .
- This invention also provides a pharmaceutical composition for treating a human skin disorder characterized by an excess of stearoyl-CoA desaturase activity, which comprises a therapeutically effective amount of the instant antibody and a pharmaceutically acceptable carrier for use m topical administration.
- This invention further provides an expression vector suitable for use in gene therapy, which vector encodes a nucleic acid molecule capable of specifically inhibiting the expression of human skin stearoyl-CoA desaturase .
- This invention further provides a pharmaceutical composition for treating a human skin disorder characterized by an excess of skin stearoyl-CoA desaturase activity, which comprises the instant expression vector, and a pharmaceutically acceptable carrier for use m topical administration.
- This invention still further provides a method for treating a human subject afflicted with a skin disorder characterized by an excess of stearoyl-CoA desaturase activity, which comprises topically administering to the subject a therapeutically effective dose of the instant SCD activity-reducing pharmaceutical composition.
- This invention provides an SCD-encodmg DNA expression vector suitable for use in gene therapy.
- This invention also provides a pharmaceutical composition for treating a human skin disorder characterized by insufficient skin stearoyl-CoA desaturase activity, which comprises the instant SCD- encodmg expression vector, and a pharmaceutically acceptable carrier for use m topical administration.
- This invention further provides a method for treating a human subject afflicted with a skin disorder characterized by insufficient stearoyl-CoA desaturase activity, which comprises topically administering to the subject a therapeutically effective dose of the instant SCD activity-increasing pharmaceutical composition.
- This invention provides the instant antibody labeled with a detectable marker.
- This invention also provides an antigen suitable for use in generating the instant antibody, which comprises at least a portion of human stearoyl-CoA desaturase.
- This invention also provides a method of producing the instant antibody, which comprises the steps of administering to a suitable animal an antigenic portion of human stearoyl-CoA desaturase, and after a suitable length of time, isolating the antibody generated by the animal against the antigenic portion so administered.
- This invention further provides a method of diagnosing a human subject for a skin disorder characterized by an abnormal level of stearoyl-CoA desaturase expression, which comprises (i) obtaining a stearoyl-CoA desaturase-containing sample from the subject's skin; (ii) contacting the sample so obtained with an excess of the instant antibody under conditions permitting binding of the antibody with stearoyl-CoA desaturase present in the sample; (iii) removing unbound antibody from the sample; (iv) quantitatively determining the amount of bound antibody present in the sample; and (v) comparing the amount determined in step (iv) with the amount determined using a skin stearoyl- CoA desaturase sample from a normal human subject, a difference in these amounts being correlative of an abnormal level of stearoyl -CoA desaturase expression in the skin of the subject being diagnosed.
- this invention provides a transgenic mouse whose skin cells do not express any gene encoding mouse skin stearoyl -CoA desaturase having the amino acid sequence shown in Figure 1 or 2 , or any polymorphism thereof.
- Figure 1 shows the sense strand sequence (mRNA sequence) of M-SCD3 cDNA obtained after sequencing 5' RACE cDNA clone from mouse skin mRNA.
- the sequence corresponding to the coding sequence i.e., the protein sequence
- the M-SCD3 -specific in situ hybridization (ISH) probe is boxed.
- Figure 2 shows the sense strand sequence (mRNA sequence) of M-SCD4vl cDNA from two overlapping novel cDNA clones obtained by screening a mouse skin cDNA library with the M-SCD3 probe.
- the sequence corresponding to the coding sequence (protein sequence) is underlined.
- the boxed sequence corresponds to the 3' half of the ISH probe for M-SCD4v2 that has 100% identity with M-SCDvl.
- Figure 3 shows the homology between M-SCD3 cDNA sequence and the M-SCD4vl cDNA sequence. The regions of homology are shown with vertical lines. The protein- coding sequence is underlined. The boxed sequence on the M-SCD4vl sequence corresponds to the 3' half of the ISH probe for M-SCD4v2 that has 100% identity with M- SCDvl. The bases that are boxed on the M-SCD3 sequence correspond to the M-SCD3 -specific ISH probe.
- FIG 4 shows a comparison of the four mouse SCD cDNA sequences, i.e., M-SCD's 1, 2, 3 and 4.
- the M-SCD4 cDNA sequence is that of M-SCD4vl.
- the protein-coding region is underlined.
- the first nucleotide beginning significant homology between a sequence and one or more of the other sequences is boxed and ends with the coding region.
- Figure 5 shows the deduced protein sequence from the M- SCD3 sense strand cDNA.
- the sequence is from amino acids 1-289.
- the single code designation of amino acids is the standard biochemical single code designation for amino acids from the GCG computer program of Wisconsin Package (Genetics Computer Group, Madison, Wisconsin) .
- Figure 6 shows the complete protein-coding sequence of mouse skin SCD4vl (359 amino acids) deduced from its cDNA sequence .
- Figure 7 shows a comparison of mouse protein sequences derived from four SCD genes. The amino acid residues which are not common in all the four protein sequences are underlined. The boxed histidine residues are conserved in evolution from yeast to mammals.
- Figure 8 shows the cDNA sequence (sense strand) and protein sequence of human SCD obtained from skin.
- the ORF extends from bp 229 to bp 1308 and encodes a predicted protein sequence of 359 amino acids.
- the boxed sequence corresponds to the human ISH probe.
- Figure 9 shows a comparison between human skin cDNA and database-deposited human liver cDNA encoding SCD. Identical bases are indicated with vertical lines. All bases differing between skin and liver are indicated with boxes. The protein-coding sequence is underlined.
- Figure 10 shows a comparison between human skin cDNA and database-deposited human adipose cDNA. Identical bases are indicated with vertical lines. All bases differing between skin and adipose are indicated with boxes. The protein-coding sequence is underlined.
- Figure 11 shows a comparison of predicted amino acid sequences derived from human skin SCD, human liver SCD, and human adipose SCD. Amino acid differences are boxed. The conserved histidine residues are underlined. The adipose sequence does not contain the complete ORF.
- Figure 12 shows the cDNA sequence homology (5' end) of sense strands of the two mouse skin SCD4 variant species. The regions of homology are connected by vertical bold lines. The protein-coding region is underlined. The boxed sequence corresponds to an ISH probe that recognizes both variant forms (vl and v2) of M-SCD4.
- Figure 13 shows the cDNA sequence homology (3' end) of sense strands of the two mouse skin SCD4 variant species. The regions of homology are connected by vertical bold lines. The region of a 6-nucleotide difference at the 3' end is boxed. The protein-coding region is underlined.
- This invention relates to the diagnosis and treatment of skin disorders characterized by abnormal stearoyl-CoA desaturase expression and activity.
- the invention also relates to various means of identifying agents useful for treating such disorders.
- Underlying this invention is the surprising discovery that stearoyl -CoA desaturase in mice and, more importantly, in humans, is expressed in skin.
- Skin is a lipid-rich organ, and many skin disorders such as atopic dermatitis and acne involve lipid imbalances.
- this invention provides a nucleic acid molecule encoding the human stearoyl-CoA desaturase having the amino acid sequence shown in
- Figure 8 or a polymorphism thereof.
- a polymorphism of the SCD whose sequence is shown in Figure 8 means any naturally occurring human SCD whose amino acid sequence varies therefrom due to one or more intra-species mutations.
- the instant SCD-encoding nucleic acid molecule can be any type of nucleic acid molecule, such as mRNA and DNA.
- the instant nucleic acid molecule is a DNA molecule.
- DNA molecules envisioned in this invention include, by way of example, cDNA molecules, which can optionally be isolated molecules.
- the nucleic acid molecule is a cDNA molecule comprising the sequence shown in Figure 8.
- the instant SCD- encoding DNA molecule can be any form of DNA permitting the expression thereof, or any form of DNA, such as an insert, which serves as a precursor to a form permitting expression.
- the DNA molecule is in an expression vector.
- SCD Stearoyl-CoA desaturase
- H-SCD human SCD
- H-SCD human SCD
- M-SCDl mouse SCDl
- M-SCD2 SCD3
- M- SCD4 SCD4
- M-SCD3 and M-SCD4 are novel genes discovered as disclosed hereinbelow.
- H-SCD sequence alternatively identified herein either as “skin H-SCD” or “HS-SCD” is novel and is expressed in skin, as well as other tissues.
- the terms “skin SCD”, “HS- SCD”, “liver SCD”, “HL-SCD”, “adipose SCD” and “HA-SCD” are intended solely to indicate the organ from which their respective SCD-encoding mRNA's were obtained, and not to indicate that these organs are the only ones in which those SCD's are respectively expressed.
- H-SCD' s identified herein as HA-SCD and HL- SCD not only differ in sequence from the instant HS- SCD, but, based on experimental discrepancies, may be polymorphisms of HS-SCD, erroneously sequenced non-HS- SCD's, or non-human SCD's entirely.
- the instant HS-SCD is the first human SCD gene ever identified.
- the terms "human stearoyl-CoA desaturase", "H-SCD” and "HS-SCD”, as they relate to the instant invention shall mean only the protein whose sequence is provided in Figure 8, and polymorphisms thereof.
- HL-SCD and HA-SCD are included herein solely for the sake of comparison to the instant HS-SCD.
- This invention also provides a nucleic acid molecule which, under suitable conditions, specifically hybridizes to a nucleic acid molecule encoding the human stearoyl -CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof.
- this nucleic acid molecule which is preferably a DNA molecule, functions as a probe to detect and/or quantitate human stearoyl-CoA desaturase- encoding nucleic acid molecules in a sample. Accordingly, in the preferred embodiment, the molecule is labeled with a detectable marker.
- the instant nucleic acid molecule "specifically hybridizes" with the H-SCD sequence if it hybridizes to that sequence, but not to any other SCD sequence to a significant degree. Ideally, the instant nucleic acid molecule hybridizes to the H-SCD-encoding molecule at least 10- fold more strongly than to any other human mRNA or cDNA. Detectable markers such as radiolabels and fluorescent labels, and methods of using same to label nucleic acid molecules, are well known in the art
- the condition suitable for hybridizing is a stringent hybridizing condition described in Sambrook, J., et al . (1989).
- This invention further provides a method of diagnosing a human subject for a skin disorder characterized by an abnormal level of stearoyl-CoA desaturase expression, which comprises (i) obtaining a sample of skin mRNA from the subject; (ii) contacting the sample so obtained with an excess of the instant labeled nucleic acid molecule under conditions permitting hybridization of the labeled nucleic acid molecule with stearoyl-CoA desaturase mRNA present in the sample; (iii) removing un-hybridized labeled nucleic acid molecule from the sample; (iv) quantitatively determining the amount of hybridized labeled nucleic acid molecule present in the sample; and (v) comparing the amount determined in step (iv) with the amount determined using a skin mRNA sample from a normal human subject, a
- Skin disorders that can be diagnosed by the instant method include, for example, skin cancer, acne, atopic dermatitis, alopecia, hirsutism, and hypertrichosis.
- Methods for obtaining tissue-specific mRNA samples e.g. skin mRNA
- conditions permitting hybridization therewith by the instant labeled nucleic acid molecule and methods of quantitatively determining the amount of hybridization by the labeled molecule, are all well known in the art (Farrell Jr. , 1993).
- This invention further provides an isolated human stearoyl -CoA desaturase encoded by the instant nucleic acid molecule.
- the isolated desaturase has the amino acid sequence shown in Figure 8.
- the "isolated" H-SCD protein is free of any other SCD protein.
- the isolated H-SCD protein is free of any other protein.
- Methods that can be used for making the H-SCD protein such as recombinant protein production and transfected cell culturing, are well known (Sambrook, et al . 1989) .
- Methods that can be used for isolating H-SCD protein such as column chromatography and gel electrophoresis, are also well known (Sambrook, et al. 1989) .
- This invention further provides a eukaryotic cell line which expresses human stearoyl-CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, wherein the cell is transfected with an expression vector encoding the desaturase.
- Suitable eukaryotic cell lines include, but are not limited to, yeast cells, insect cells and animal cells.
- Suitable animal cells include, but are not limited to HeLa cells, Cos cells, CV1 cells and various primary mammalian cells. Numerous mammalian cells may be used as hosts, including, but not limited to, the mouse fibroblast cell NIH-3T3 cells, CHO cells, HeLa cells, Ltk " cells and COS cells.
- the eukaryotic cell line is a mammalian cell line, ideally one comprising, or derived from, skin tissue cells.
- the eukaryotic cell lines may be transfected by methods well known in the art such as calcium phosphate precipitation, electroporation, lipofection, and microinj ection.
- This invention provides several methods of screening agents for therapeutic and prophylactic use in connection with SCD-related disorders.
- this invention provides a method for determining whether an agent increases the expression level of human stearoyl- CoA desaturase in skin cells already expressing same, which comprises the steps of (i) contacting the agent under suitable conditions with a eukaryotic cell line expressing human stearoyl -CoA desaturase at a known level; and (ii) determining whether the stearoyl -CoA desaturase expression level increases after cellular contact with the agent, thereby determining whether the agent increases the expression level of human stearoyl- CoA desaturase in skin cells already expressing same.
- this invention provides a method for determining whether an agent decreases the expression level of human stearoyl-CoA desaturase in skin cells already expressing same, which comprises the steps of
- the amount by which the H-SCD expression level is increased or decreased can be any quantifiable amount. In the preferred embodiment, this amount is at least a 50% increase or decrease in expression level .
- Methods which can be used for quantitatively determining such increase or decrease include, for example, labeled probe hybridization with skin mRNA Northern blots, and are well known in the art (Farrell, Jr. 1993) .
- the eukaryotic cell line can be either (a) a cell line transfected with an expression vector encoding a human stearoyl -CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, or (b) a non-transfected cell line.
- this invention provides a method for determining whether an agent decreases the activity of human stearoyl-CoA desaturase in skin cells, which comprises the steps of (i) contacting the agent under suitable conditions with human stearoyl -CoA desaturase having a known level of activity; and (ii) determining whether the desaturase activity decreases after contact with the agent, thereby determining whether the agent decreases human stearoyl -CoA desaturase activity in skin cells.
- this invention provides a method for determining whether an agent increases the activity of human stearoyl-CoA desaturase in skin cells, which comprises the steps of (i) contacting the agent under suitable conditions with human stearoyl -CoA desaturase having a known level of activity; and (ii) determining whether the desaturase activity increases after contact with the agent, thereby determining whether the agent increases human stearoyl -CoA desaturase activity in skin cells.
- "activity of H-SCD” means the rate at which the SCD introduces a cis-double bond in its substrate palmitate to produce palmitoleoyl -CoA.
- Methods that can be used to quantitatively measure SCD activity include, for example, measuring thin layer chromatographs of SCD reaction products over time. This method and others methods suitable for measuring SCD activity are well known (Henderson, et al . 1992).
- This invention also provides an antibody which specifically binds to human stearoyl -CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, and thereby inhibits the activity thereof.
- the instant antibody can be a polyclonal antibody, a monoclonal antibody, or an SCD-binding fragment thereof.
- the antibody is an isolated antibody, i.e., an antibody free of any other antibodies.
- the term "antibody” includes, by way of example, both naturally occurring and non-naturally occurring antibodies.
- the term “antibody” includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. Methods of making and isolating antibodies are well known in the art (Harlow, et al . 1988).
- This invention further provides a pharmaceutical composition for treating a human skin disorder characterized by an excess of stearoyl -CoA desaturase activity, which comprises a therapeutically effective amount of the instant antibody and a pharmaceutically acceptable carrier for use in topical administration.
- topically administering the instant pharmaceutical compositions can be effected or performed using any of the various methods and delivery systems known to those skilled in the art.
- the topical administration can be performed, for example, transdermally and via topical injection.
- compositions for topical administration are well known in the art, as are methods for combining same with active agents to be delivered.
- topical carriers and their uses are well known in the art (Ramchandani ; Barry; Wenniger; Martindale's Parmacopoeia; U.S. Pharmacopeoia) .
- the following dermal delivery systems, which employ a number of routinely used carriers, are only representative of the many embodiments envisioned for administering the instant composition.
- Transdermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone) .
- the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer.
- liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N I ,N II ,N III -tetramethyl-N,N I ,N II ,N III -tetrapalmityl- spermine and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL) ; (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N- [1- (2 , 3 -dioleoyloxy) -N,N,N- trimethyl-ammoniummethylsulfate) (Boehringer Manheim) ; and (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL) .
- DOPE diole
- This invention still further provides an expression vector suitable for use in gene therapy, which vector encodes a nucleic acid molecule capable of specifically inhibiting the expression of human skin stearoyl-CoA desaturase.
- the nucleic acid molecule is an anti-sense molecule which is complementary to, and specifically hybridizes with, at least a portion of human stearoyl-CoA desaturase mRNA.
- anti-sense nucleic acid technology has been one of the major tools of choice to inactivate genes whose expression causes disease and is thus undesirable.
- the anti-sense approach employing a nucleic acid molecule that hybridizes with an mRNA molecule encoding an undesirable gene, leads to the inhibition of gene expression.
- Methods of making and using anti -sense molecules against known target genes are known in the art (Agrawal , 1996) .
- This invention still further provides a pharmaceutical composition for treating a human skin disorder characterized by an excess of skin stearoyl - CoA desaturase activity, which comprises the instant expression vector, and a pharmaceutically acceptable carrier for use in topical administration.
- This invention also provides a method for treating a human subject afflicted with a skin disorder characterized by an excess of stearoyl -CoA desaturase activity, which comprises topically administering to the subject a therapeutically effective dose of the instant SCD activity-reducing pharmaceutical composition.
- the disorder is selected from skin cancer, hypertrichosis, and hirsutism.
- Determining a therapeutically effective dose of the instant pharmaceutical composition can be done based on animal data using routine computational methods.
- the therapeutically effective dose contains between about 1 ⁇ g and about 1 g of the instant activity-reducing vector.
- the therapeutically effective dose contains between about 10 ⁇ g and about 100 mg of the vector.
- the therapeutically effective dose contains between about 100 ⁇ g and about 10 mg of the vector.
- This invention provides an SCD-encoding DNA expression vector suitable for use in gene therapy.
- This invention also provides a pharmaceutical composition for treating a human skin disorder characterized by insufficient skin stearoyl -CoA desaturase activity, which comprises the instant SCD- encoding expression vector, and a pharmaceutically acceptable carrier for use in topical administration.
- This invention further provides a method for treating a human subject afflicted with a skin disorder characterized by insufficient stearoyl -CoA desaturase activity, which comprises topically administering to the subject a therapeutically effective dose of the instant SCD activity-increasing pharmaceutical composition.
- the disorder is selected from acne, atopic dermatitis and alopecia.
- the therapeutically effective dose contains between about 1 ⁇ g and about 1 g of the instant SCD-encoding vector. In another embodiment, the therapeutically effective dose contains between about 10 ⁇ g and about 100 mg of the vector. In a further embodiment, the therapeutically effective dose contains between about 100 ⁇ g and about 10 mg of the vector.
- This invention provides the instant antibody labeled with a detectable marker.
- This invention also provides an antigen suitable for use in generating the instant antibody, which comprises at least a portion of human stearoyl -CoA desaturase.
- This invention also provides a method of producing the instant antibody, which comprises the steps of administering to a suitable animal an antigenic portion of human stearoyl -CoA desaturase, and after a suitable length of time, isolating the antibody generated by the animal against the antigenic portion so administered.
- Suitable animals include, by way of example, mammals such as mice, rabbits, goats, and monkeys.
- Suitable lengths of time for generating antibodies are well known in the art, and often include one or more "booster" administrations subsequent to the initial antigen administration.
- the antigen is administered along with an adjuvant according to well known methods .
- This invention further provides a method of diagnosing a human subject for a skin disorder characterized by an abnormal level of stearoyl-CoA desaturase expression, which comprises (i) obtaining a stearoyl -CoA desaturase-containing sample from the subject's skin; (ii) contacting the sample so obtained with an excess of the instant antibody under conditions permitting binding of the antibody with stearoyl-CoA desaturase present in the sample; (iii) removing un- bound antibody from the sample; (iv) quantitatively determining the amount of bound antibody present in the sample; and (v) comparing the amount determined in step (iv) with the amount determined using a skin stearoyl- CoA desaturase sample from a normal human subject, a difference in these amounts being correlative of an abnormal level of stearoyl -CoA desaturase expression in the skin of the subject being diagnosed.
- Conditions required for antibody binding are well known.
- the antibody can be labeled or unlabeled
- transgenic mouse whose skin cells do not express any gene encoding mouse skin stearoyl-CoA desaturase having the amino acid sequence shown in Figure 1 or 2 , or any polymorphism thereof.
- This type of transgenic mouse is also known in the art as a "knock-out mouse” , in that its transgenic status inhibits the expression of an undesired gene.
- the transgenic mouse has operably integrated into its chromosomes a DNA sequence encoding human stearoyl -CoA desaturase having the amino acid sequence shown in Figure 8 or a polymorphism thereof, which desaturase is expressed in the mouse's skin cells.
- this invention also provides, mutatis mutandis, the corresponding embodiment of each of mouse SCD genes 3 and 4.
- mutant mouse known as aseJbia, discussed in more detail hereinabove, was chosen as an experimental focal point.
- the most obvious phenotype is early loss of hair and hypoplasia of the sebaceous gland.
- M-SCD3 and M-SCD4 are located in the keratinocyte matrix cells of the hair follicle and in the sebaceous gland.
- HSDCD human SCD
- SCD4 SCD4 sequence was derived from overlapping sequences of two clones - 15g and 7d. A variant of the SCD4 sequence was identified after sequencing another clone - clone 5a. The former is identified herein as "SCD4vl" (variant 1) and the latter (derived from 5a clone) as “SCD4v2" (variant 2) .
- M-SCD3 clone The entire sequence of M-SCD3 clone (up to exon 5) is shown in Figure 1.
- An open reading frame for protein starts from nucleotide 285, and that part of the sequence is underlined. In addition to the coding sequence, it has 284 nucleotides of 5' non-coding sequence.
- Sequence comparison with the known M-SCDl indicates that -145 nucleotides at the 5' end of SCD3 are unique, whereas the rest of the sequence is highly homologous to the mouse SCDl sequence (-99% identity) .
- sequence comparisons with the known mouse SCD2 showed that the region of dissimilarity (unique 5' end of SCD3) stretched down to about 280 nucleotides.
- the region downstream of 280 nucleotides of SCD3 which encompasses the protein-coding region, shows only -90% identity with the SCD2 sequence.
- the region of homology between SCD3 and SCDl includes both the protein-coding region and a part of 5' non-coding region, the identity between SCD3 and SCD2 is limited to the protein-coding region of the genes.
- the nucleotide sequence of one of the isoforms of SCD4, SCD4vl is shown in Figure 2.
- the sequence encompasses the entire protein-coding sequence (underlined) with 317 and 179 nucleotides of 5' and 3' UTR, respectively.
- Sequence comparison with the M-SCDl sequence reveals that that the region of homology is limited to only the protein-coding sequence (underlined) ( ⁇ 91%identity) , with no significant homology in either 5' or 3 ' non-coding regions.
- the sequence comparison with the M-SCD2 cDNA sequence again indicated a homologous region limited to the protein- coding segment (underlined) , with sequence identity of about 88%.
- SCD4 cDNA Two distinct clones of SCD4 cDNA were identified, as indicated by unique sequences in both the 5' untranslated region ( Figure 12) and 3' untranslated region ( Figure 4) . These two species may be alternative splice forms of the SCD4 gene, both of which are expressed in mouse skin. Alternatively, they may represent sequences from two SCD4 genes. These clones are unlikely to be cloning artifacts, since the difference was also noted at the 3' end just prior to the poly A stretch in the two sequences as shown in Figure 4 (boxed region of 6 nucleotides) . The protein- coding regions are underlined, and are identical as between these two variants.
- M-SCD3 cDNA The longest ORF of M-SCD3 cDNA that also has a high degree of homology to SCDl protein-coding sequence is shown in Figure 5. Although this sequence lacks the exon 6 sequence, it represents the sequence up to the end of exon 5, as indicated by homology to the M-SCDl sequence. This identifies it as a bonafide member of the SCD family. M-SCD3 cannot be a splice variant of the SCDl gene, since the differences m nucleotides that lead to a single ammo acid change of alan e to cysteme at position 97 of the SCD3 protein sequence occur withm an exon. In addition, SCD3 cDNA has a unique 3' non-coding sequence.
- Figure 7 snows a comparison of mouse SCDl, SCD2 , SCD3 and SCD4 protein sequences.
- SCDl has an identical protein sequence to that of SCD3 , except for one ammo acid position wnere the alanme in SCDl is replaced by cysteme m SCD3 (position 101 in Figure 7) .
- SCD2 and SCD4 are more divergent and have more ammo acid differences, wnich are not shared by SCDl or SCD3. Those ammo acids which differ between all four SCD's are underlined.
- the conserved histidme ammo acid residues m mammals, yeast and other lower species are boxed at positions 120, 125, 157, 160, 161, 298, 301, and 302 in Figure 7.
- the positions and the neighboring ammo acid residues of these histidme regions are conserved m all four mouse protein sequences (SCD1-4) as shown m Figure 7.
- a 129 bp fragment (Notl digest of 5 ⁇ 5 plasmid) containing the sequence from the 5' UTR that is unique o M-SCD3 was cloned into the PBluescript KS vector (Stratagene) , and was used for generating ⁇ boprobes .
- the M-SCD3 -specific sequence is shown as boxed in Figure 1.
- the relationship of the M-SCD3 -specific sequence (boxed) to that of M-SCD4vl is shown in Figure 3.
- the dorsal skin of an adult C57B1/6 mouse was excised and frozen in OCT embedding compound. Frozen sections were collected on positively-charged glass slides.
- M-SCD3 -unique plasmid was first linearized with Sacl and labeled with digoxigenm using T7 RNA polymerase according to manufacturer's instructions (Boehr ger-Manheim) .
- a sense, digoxigenm- labeled ⁇ boprobe was generated jsmg T3 RNA polymerase with a BamHl - linearized plasmid.
- In situ hybridization was carried out according to standard procedures (Hebert, et al . 1991). The results, not shown here, indicate that M-SCD3 is primarily expressed m matrix keratinocytes of the hair follicle and not m the sebaceous gland.
- M- SCD3 in matrix keratinocytes suggests an important role for M-SCD3 either proliferation and/or differentiation of these cells.
- Cotsarelis, et al . (1990) have reported that, using t ⁇ tiated thymidme, these cells are highly proliferative and comprise the transien -amplifying ste cells of the hair follicle.
- M-SCD3 may not function at this site.
- M-SCD4 may have a role m sebaceous function.
- a 223 bp fragment (EcoRl-Sphl digest of clone 5a) containing the entire 5' UTR of M-SCD4v2 was cloned into the PBluescript SK vector (Stratagene) . Position 130 to 225 of the M-SCD4v2 sequence is 100% identical to that of M-SCD4vl. Thus, this probe recognizes both variant forms of M-SCD4.
- Mouse skin for ISH was prepared as described above.
- An anti-sense, digoxigenm- labeled riboprobe was generated using T7 RNA polymerase with a EcoRl- linearized plasmid.
- a sense, digoxigenm- labeled riboprobe was generated using T3 RNA polymerase with a Kpnl -digested plasmid.
- ISH was carried out as described above.
- M-SCD4 is strongly expressed the matrix keratinocytes of the hair follicle.
- Sebaceous glands express M-SCD4.
- the follicular papilla ("FP") of hair follicles and epidermis do not express M-SCD4.
- Adjacent follicular papilla fibroblascs are negative for M-SCD4 mRNA.
- Sebaceous glands specifically express M-SCD4 in the lower aspect of the gland, although some sebaceous glands do not express significant amounts of M-SCD4. The reasons for this are not clear at present, but may be related to heterogeneity of M-SCD4- express g cells within the gland, cyclical expression in glands, or plane of section of the tissue sample.
- M-SCD4 Based on the expression pattern and putative function of SCD, M-SCD4 apparently plays a role m both hair follicle growcn and sebaceous gland function. That M-SCD4, and not M-SCD3, is expressed sebaceous glands is consistent with the expression of FAR17c, which is the hamster homolog of M-SCD4. FAR17c is more related to M-SCD4 than to M-SCD3 m cDNA and protein sequence. FAR17c was isolated from hamster flank organ, a tissue comprised mostly of sebaceous cells. No localization data are presented in the work on FAR17c, thus this localization of M-SCD4 to sebaceous glands represents the first anatomical localization of SCD to vertebrate sebaceous glands.
- M-SCD4 and M-SCD3 in the matrix keratinocytes suggests that redundancy may be related to a critical role for this enzyme in matrix cell physiology. It is notable that no expression is seen in the epidermis, a site of putative epidermal stem cells, suggesting that M-SCD3 and 4 may have a function specific to hair follicle (and possible sebaceous gland) stem cells.
- PCR was used to amplify the complete open reading frame (ORF) , as well as to generate probes, from cDNA of human scalp PSU's. These probes were used to screen a human foreskin keratmocyte cDNA library, from which the 5' untranslated region (UTR) , the complete ORF, and part of the 3' UTR were cloned.
- ORF open reading frame
- UTR 5' untranslated region
- HS-SCD Expression of HS-SCD is present in the matrix keratinocytes of the hair follicle and m the sebaceous gland.
- mice do not have eccrme sweat glands in their hair-bearing skin.
- a pair of primers forward: 5 ' GATATCTCAAGCTCCTATACC3 ' , reverse : 5 ' CTCCTCTGGAACATCACCAGTT3 '
- HA-SCD Figure 10
- the PCR fragment was cloned into the PBluescript vector and then used to generate a cDNA probe to screen a human foreskin keratinocyte (HFKC) cDNA lambda library constructed in ⁇ gtll (Clontech #HL1110B) .
- HFKC human foreskin keratinocyte
- cDNA sequences from the HFKC library indicate a C at position 898 (see Figure 8) , which results the ammo acid leuc e.
- cDNA sequences of "uncloned" PCR products from the hair plugs indicate both a C and A at position 898, indicating that individual SCD transcripts from hair plug have either a C (producing leucme at ammo acid 224) or an A (producing methion e at ammo acid 224) at position 898 of the cDNA sequence.
- Figures 8-11 all HS-SCD sequences are reported as C at position 898 of cDNA.
- the ammo acid sequence in Figure 11 is reported with leucme at position 224. Since the hair plug samples are pooled from several individuals, the changes seen at bp 898 may be due to polymorphism.
- the ORF s 1080 bp and generates a predicted protein of 359 ammo acids. Included m the human skin cDNA is 228 bp of 5' UTR and 689 bp of 3' UTR.
- the cDNA sequences of human skm and liver SCD are 97.9% identical at the nucleotide level and 98.3% identical at the protein level.
- the most significant base transitions are bp 301 and bp 304.
- the substitution at these sites in liver vs skm result in ammo acid substitutions of prolme to serme (ammo acid 25) and m glycine to arginine (ammo acid 26) , respectively ( Figure 11) .
- the substitution of serme for prolme in the skm cDNA may increase the polarity and may alter the secondary structure conferred by prolme.
- the dramatic substitution of arginine for glycine in the skm cDNA replaces a nonpolar ammo acid with a postively charged ammo acid, which may result m an altered surface profile.
- the 5' UTR contains 20 bp of unique sequence not present the liver cDNA.
- the 3' UTR contains an additional 508 bp not contained in the liver cDNA.
- the significance of the base pair differences m the UTR's is unknown. However, these differences may result m altered stability of the mRNA.
- the 17 differences in the 3' UTR are mostly associated with the stretch of A's present in the liver cDNA.
- the human adipose SCD represents a partial cDNA that is completely contained within the ORF of HS-SCD and HL-SCD.
- the skin cDNA sequence that overlaps the adipose cDNA sequence is 97.8% identical.
- the overlapping protem-codmg sequence is 97.4% identical.
- the cDNA sequence of skm contains 15 base changes from the adipose cDNA sequence as seen in Figure 10. Of the 15 differences in the ORF, 6 lead to ammo acid changes. Of these 6 changes, 5 of 6 base substitutions occur either at the first or second position of the codon.
- the base substitutions m the ORF of adipose compared to skm are as follows (using skm as the reference) : bp 241: A to T, bp 246: C to G, bp 249: A to G, bp 252: G to C, bp 261: A to T, bp 300: T to C, bp 301: C to T, bp 303: A to C, bp 304: G to A, bp 393: C to T, bp 888: C to T, bp 898: A to C, bp 936: C to T, bp 938: G to T, and bp 945: C to T ( Figure 10) .
- substitutions are bp 301 and 304.
- the substitution at 301 results in prolme to serme, and the substitution at 304 results m glycine to arginine (Figure 10) .
- These are the same changes m ammo acids 25 and 26 that are seen m HL-SCD cDNA as compared to HS-SCD cDNA.
- the suost tution of T for G at bp 938 of HS-SCD results in replacement of cysteme with phenylalanme at ammo acid 237, which may change secondary structure via altered disulfide bridges.
- the substitions (in skm cDNA from adipose cDNA) at bp 241, 252, and 898 result m the replacement of ammo acid residues of similar biochemical profile. These replacements are: methionme to leucme (nonpolar), glutamate to aspartate (acidic) , and methionme to leucme (nonpolar) , respectively.
- the base changes at 246, 249, 261, 393, 888, 936, and 945 do not result in ammo acid changes.
- HS-SCD is a highly related, but unique sequence from HL-SCD and HA-SCD.
- HS-SCD contains a serme and arginine at ammo acids 24 and 25, wnere both HL-SCD and HA-SCD contain prolme and glycine at these positions.
- These particular substitutions, resulting m substitutions of adjacent ammo acids, are corroborated by the same serme and arginine found in the porcine SCD. No substitution between skm, liver, and adipose SCD disrupts or occurs withm the conserved histidme motifs as indicated by underlining m Figure 11.
- the ISH probe used for localization of HS-SCD m skm is the same as that used to screen the HFKC cDNA library, as described above, and is shown boxed in Figure 8.
- This region is highly homologous to the corresponding regions of liver SCD and adipose SCD, and thus would be expected to cross react in any procedure utlizing hybridization.
- liver or adipose SCD sequences be detected in hair plug cDNA or in the HFKC library when sequencing both cloned and un-cloned PCR products. Nevertheless, a possible polymorphism was detected at bp 898. No other base positions were called ambiguously (an N in the base sequence, indicating "any" base) .
- skm only expresses the skm SCD sequence as given m Figure 8.
- the ISH probe although based on a common region of cDNA, snould only detect the skm SCD on tissue sections of hair plug samples .
- the matrix keratinocytes of the hair bulb strongly and specifically expresses HS-SCD as indicated by data not shown here.
- Adjacent FP fibroolasts ⁇ o not express HS-SCD. This expression pattern is strikingly similar to that of mouse. Although expressed less prominently than in the matrix cells, HS-SCD is specifically expressed in the human sebaceous gland.
- Eccrine sweat glands specifically express HS-SCD.
- the presence of HS-SCD in eccrine sweat gland suggests that HS-SCD may function in the growth regulation of the eccrine sweat gland cells and/or modification of the lipid contained m sweat .
- SCD mRNA is highly expressed in the hair matrix keratinocytes of both mouse and human, suggesting a phylogenetically conserved function.
- Cell division is highly conserved throughout evolution. Increased SCD has been found in several human tumors (Li et al . , 1994), and is up- regulated in cells tnat are placed m culture and undergoing rapid growth as determined here by experiment. Similarly, it is down-regulated in cells that have stopped dividing, as determined here by experiment .
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9652098P | 1998-08-14 | 1998-08-14 | |
US96520P | 1998-08-14 | ||
US36858299A | 1999-08-05 | 1999-08-05 | |
PCT/US1999/018387 WO2000009754A2 (fr) | 1998-08-14 | 1999-08-12 | COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES |
2003-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1105538A2 true EP1105538A2 (fr) | 2001-06-13 |
Family
ID=26791780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99945051A Withdrawn EP1105538A2 (fr) | 1998-08-14 | 1999-08-12 | COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1105538A2 (fr) |
JP (1) | JP2003533965A (fr) |
CA (1) | CA2339748A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003215203A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Short interfering nucleic acid inhibition of stearoyl-coa desaturase (scd) gene |
US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
US20140154206A1 (en) * | 2011-05-19 | 2014-06-05 | Toray Industries, Inc. | Immunity induction agent |
WO2018008319A1 (fr) * | 2016-07-08 | 2018-01-11 | 花王株式会社 | Procédé de préparation d'échantillon d'acide nucléique |
-
1999
- 1999-08-12 CA CA002339748A patent/CA2339748A1/fr not_active Abandoned
- 1999-08-12 JP JP2000565188A patent/JP2003533965A/ja not_active Ceased
- 1999-08-12 EP EP99945051A patent/EP1105538A2/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0009754A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2339748A1 (fr) | 2000-02-24 |
JP2003533965A (ja) | 2003-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000009754A2 (fr) | COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES | |
Hojjati et al. | Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice | |
Kazantzis et al. | Fatty acid transport proteins, implications in physiology and disease | |
O'Malley et al. | Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5'alternative splice sites responsible for multiple mRNAs | |
Rydén et al. | Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis | |
Smith et al. | Cellular localization of apolipoprotein D and lecithin: cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization. | |
Binczek et al. | Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation | |
Ang et al. | Expression patterns of class I and class IV alcohol dehydrogenase genes in developing epithelia suggest a role for alcohol dehydrogenase in local retinoic acid synthesis | |
Keeney et al. | Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity | |
JP4298801B2 (ja) | ミクロソームトリグリセリド転移蛋白質 | |
Gao et al. | Enhanced susceptibility of Cpt1c knockout mice to glucose intolerance induced by a high-fat diet involves elevated hepatic gluconeogenesis and decreased skeletal muscle glucose uptake | |
Li et al. | The expression of epidermal lipoxygenases and transglutaminase-1 is perturbed by NIPAL4 mutations: indications of a common metabolic pathway essential for skin barrier homeostasis | |
Isosomppi et al. | Developmental expression of palmitoyl protein thioesterase in normal mice | |
JP2002525111A (ja) | 脂質障害および炎症性疾患の診断および治療のためのatp結合カセット遺伝子およびタンパク質 | |
Otsuka et al. | Formation of fatty alcohols—components of meibum lipids—by the fatty acyl‐CoA reductase FAR2 is essential for dry eye prevention | |
Yang et al. | Adipocyte-specific modulation of KLF14 expression in mice leads to sex-dependent impacts on adiposity and lipid metabolism | |
KR100516561B1 (ko) | 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법 | |
Buccafusca et al. | Characterization of the null murine sodium/myo-inositol cotransporter 1 (Smit1 or Slc5a3) phenotype: myo-inositol rescue is independent of expression of its cognate mitochondrial ribosomal protein subunit 6 (Mrps6) gene and of phosphatidylinositol levels in neonatal brain | |
Ohmori et al. | Thioredoxin deficiency increases oxidative stress and causes bilateral symmetrical degeneration in rat midbrain | |
EP1105538A2 (fr) | COMPOSITIONS ASSOCIEES A LA STEAROYL-CoA DESATURASE HUMAINE ET PROCEDES DE TRAITEMENT D'AFFECTIONS CUTANEES | |
Connor et al. | Transferrin in the central nervous system of the shiverer mouse myelin mutant | |
CA2299617A1 (fr) | Materiels de 1-a-alpha-hydroxylase et ses procedes | |
Ideta et al. | Sequence analysis and characterization of FAR-17c, an androgen-dependent gene in the flank organs of hamsters | |
Cyriac et al. | Androgen regulation of spermidine synthase expression in the rat prostate | |
Holtzman et al. | Prostaglandin H Synthase and Lipoxygenase Gene Families in the Epithelial Cell Barrier a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010302 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZHANG, LIN Inventor name: PARIMOO, SATISH Inventor name: PROUTY, STEPHEN, M. Inventor name: STENN, KURT |
|
17Q | First examination report despatched |
Effective date: 20050310 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050721 |